Monday, April 29, 2024
Home Ark versus Sark

Ark versus Sark

    Random

    Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.

    Ark versus Sark Editor / Curator -
    Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.

    ARK VS. SARK | PAST STANCES

    Ark versus Sark Editor / Curator -
    Long SARK 3-13-2023 | $44.21 Long Ark Innovation 10-3-2022 |...

    Latest article

    Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

    2024 Watch List Editor / Curator -
    CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

    GeoVax (GOVX) Launches Vaccine Manufacturing System.

    2024 Watch List Editor / Curator -
    GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...

    Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...

    All News Editor / Curator -
    Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.